GREY:BIOAF - Post by User
Comment by
prophetoffactzon Jan 09, 2023 9:48pm
94 Views
Post# 35212529
RE:RE:RE:RE:RE:Chiesi
RE:RE:RE:RE:RE:Chiesi".... but JD I am going to say that maybe just maybe Chiesi knows more than about xB3 than you!
To me it's pretty clear they are not interested in xB3!"
That's not the distinct impression BTI left in its recent presentation concerning the merger. Rathjen, Saltarelli and Mei Mei are also on Chiesi's xB3 Advisory Board and they switched BTI's lead xB3 asset from xB3-001 to a Lysosomal Storage Disorder(Hunter) which is what Chiesi is focused on. Would BTI have done that if Chiesi hit a roadblock? Biodexa also afirms Hunter as its lead xB3 asset. Preclinical results for Hunter are expected in Q2. To compete in Hunter BTI has to go head-to-head against Denali which has a lead in Hunter of years. The Chiesi results should be pretty good. Being on Chiesi's xB3 Advisory Board Saltarelli has also stayed with BTI and now Biodexa. He doesn't have to stay and could easily go elsewhere given his history of success. BTI also changed its strategic focus to Lysosomal Storage Disorders, inflammation, and neurodegeneration. It also signed the deal with Oxyrane for Gaucher's which is the largest Lysosomal Storage Disorder.
Chiesi could have European and US FDA approval for Fabry in the first half of this year. This could make it a strategic player in Lysosomal Storage. If it wants to build on its position Lysosomal Storage its interest in xB3 will be key as the rush to deliver enzyme to the brain is underway. Denali is leading the way. Biodexa's preclinical results to be released in Q2 may show why Bodexa is willing to go head-to-head against Denali.
.